[Onco-cardiology in hematological malignancy: from the perspective of cardiology].

Recent advances in cancer therapy have improved the long-term outcomes of cancer patients, increasing the importance of managing cardiovascular complications arising not only from cancer itself but also from chemotherapy, radiation therapy, and immunotherapy. In the field of hematology, there are serious concerns about cardiovascular complications of various chemotherapeutic agents such as anthracyclines, immunomodulatory drugs, BCR-ABL tyrosine kinase inhibitors, proteasome inhibitors, and immune checkpoint inhibitors. Chemotherapy has a wide variety of effects on the cardiovascular system, and the molecular mechanisms underlying the cardiovascular toxicities of individual molecularly targeted agents remain to be precisely defined. This "Onco-Cardiology" approach is expected to enhance interdisciplinary collaboration between oncology/hematology and cardiology specialists across clinical practice, research, and education to protect cancer patients and survivors from cardiovascular complications.